Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209451 | 0.81 | PTGS2 (0.44) | PTGS2SLC6A4MAPK8ENPP2 | |
| SCHEMBL5206937 | 0.81 | DPP4 (0.44) | SLC6A4 | |
| SCHEMBL5205615 | 0.76 | CA12 (0.49) | — | |
| SCHEMBL5209631 | 0.73 | PPARG (0.43) | SLC6A4ENPP2 | |
| SCHEMBL1400620 | 0.72 | TP53 (0.55) | PTGS2 | |
| SCHEMBL31613792 | 0.72 | TP53 (0.55) | PTGS2 | |
| SCHEMBL3198824 | 0.71 | PTGDR2 (0.51) | SLC6A4 | |
| SCHEMBL8949933 | 0.70 | LTB4R (0.58) | PTGS2 | |
| SCHEMBL2662702 | 0.70 | CTNNB1 (0.66) | PTGS2SLC6A4 | |
| SCHEMBL14030895 | 0.69 | HTT (0.68) | PTGS2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1040102-B1 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1194146-B1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2006-07-19 | — | — | EP | disclosed |
| US-6645997-B2 | Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| EP-1324995-A2 | BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | Merck & Co., Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
| EP-1040102-A4 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1194146-A4 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020082292-A1 | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | MERCK SHARP & DOHME CORP. | 2002-06-27 | — | — | US | disclosed |
| US-6399640-B1 | ANTIDIABETIC AGENTS; ANTICHOLESTEROL AGENTS | MERCK & CO., INC. | 2002-06-04 | — | — | US | disclosed |
| EP-1194146-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2002026729-A2 | BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | MERCK & CO., INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6200998-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS; ANTICHOLESTEROL, ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO., INC. | 2001-03-13 | — | — | US | disclosed |
| WO-2000078312-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-1040102-A1 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | Merck & Co., Inc. (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6008237-A | POTENT AGONISTS OF PEROXIDSOME PROLIFERATOR ACTIVATED RECEPTOR; FOR CONTROLLING OR PREVENTING OF DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, OBESITY, VASCULAR RESTENOSIS | MERCK & CO., INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1999032465-A1 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082292-A1 | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | PPARD, PPARA, PPARG | PTGS2 678/4885SLC6A4 4380/4885MAPK8 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.